(cid:18)(cid:12)(cid:8)(cid:17)(cid:5)(cid:4)(cid:21)(cid:16)(cid:17)(cid:2)(cid:17)(cid:5)(cid:16)(cid:21)(cid:14)(cid:2)(cid:17)(cid:5)(cid:12)(cid:17)(cid:21)(cid:2)(cid:12)(cid:4)(cid:21)(cid:17)(cid:15)(cid:2)(cid:4)(cid:5)(cid:11)(cid:2)(cid:15)(cid:9)(cid:21)(cid:13)(cid:6)(cid:6)(cid:8)(cid:3)(cid:5)(cid:21)
`UNITED STATES PATENT AND TRADEMARKOFFICE
`
`(cid:18)(cid:22)(cid:25)(cid:37)(cid:41)(cid:22)(cid:60)(cid:44)(cid:27)(cid:22)(cid:60)(cid:39)(cid:16)(cid:60)(cid:44)(cid:22)(cid:34)(cid:44)(cid:60)(cid:44)(cid:41)(cid:28)(cid:16)(cid:31)(cid:60)(cid:16)(cid:34)(cid:21)(cid:60)(cid:16)(cid:39)(cid:39)(cid:22)(cid:16)(cid:32)(cid:60)(cid:18)(cid:37)(cid:16)(cid:41)(cid:21)(cid:60)
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`(cid:16)(cid:39)(cid:37)(cid:44)(cid:23)(cid:46)(cid:1)(cid:60)(cid:28)(cid:34)(cid:19)(cid:6)(cid:2)(cid:60)
`APOTEX,INC.,
`(cid:39)(cid:48)(cid:57)(cid:50)(cid:57)(cid:50)(cid:53)(cid:51)(cid:48)(cid:54)(cid:3)(cid:60)
`Petitioner,
`(cid:2)(cid:1)(cid:3)
`
`V.
`
`(cid:20)(cid:24)(cid:33)(cid:26)(cid:24)(cid:36)(cid:24)(cid:60)(cid:20)(cid:37)(cid:41)(cid:39)(cid:37)(cid:43)(cid:17)(cid:45)(cid:29)(cid:37)(cid:35)(cid:3)(cid:60)
`CELGENE CORPORATION,
`(cid:40)(cid:47)(cid:58)(cid:49)(cid:52)(cid:58)(cid:60)(cid:38)(cid:59)(cid:52)(cid:49)(cid:55)(cid:7)(cid:60)
`Patent Owner.
`
`(cid:20)(cid:47)(cid:56)(cid:49)(cid:60)(cid:30)(cid:40)(cid:42)(cid:10)(cid:8)(cid:10)(cid:11)(cid:5)(cid:8)(cid:8)(cid:13)(cid:9)(cid:10)(cid:60)
`Case IPR2023-00512
`(cid:40)(cid:47)(cid:58)(cid:49)(cid:52)(cid:58)(cid:60)(cid:15)(cid:4)(cid:15)(cid:12)(cid:14)(cid:4)(cid:14)(cid:10)(cid:15)(cid:60)
`Patent 8,846,628
`
`(cid:4)(cid:5)(cid:3)(cid:10)(cid:2)(cid:15)(cid:2)(cid:17)(cid:8)(cid:13)(cid:12)(cid:21)(cid:13)(cid:6)(cid:21)(cid:2)(cid:11)(cid:20)(cid:21)(cid:9)(cid:1)(cid:21)(cid:19)(cid:8)(cid:7)(cid:11)(cid:13)(cid:15)(cid:5)(cid:21)(cid:8)(cid:12)(cid:21)(cid:16)(cid:18)(cid:14)(cid:14)(cid:13)(cid:15)(cid:17)(cid:21)(cid:13)(cid:6)(cid:21)
`DECLARATION OF AMY K. WIGMOREIN SUPPORT OF
`(cid:18)(cid:12)(cid:13)(cid:14)(cid:14)(cid:13)(cid:16)(cid:5)(cid:4)(cid:21)(cid:11)(cid:13)(cid:17)(cid:8)(cid:13)(cid:12)(cid:21)(cid:6)(cid:13)(cid:15)(cid:21)(cid:2)(cid:4)(cid:11)(cid:8)(cid:16)(cid:16)(cid:8)(cid:13)(cid:12)(cid:21)(cid:6)(cid:7)(cid:5)(cid:9)(cid:3)(cid:1)(cid:9)(cid:8)(cid:4)(cid:1)(cid:2)(cid:9)
`UNOPPOSED MOTION FOR ADMISSION PRO HAC VICE
`
`(cid:38)(cid:40)(cid:47)(cid:42)(cid:40)(cid:49)(cid:40)(cid:3)(cid:21)(cid:20)(cid:24)(cid:23)
`CELGENE 2154
`(cid:36)(cid:51)(cid:50)(cid:55)(cid:40)(cid:59)(cid:3)(cid:89)(cid:17)(cid:3)(cid:38)(cid:40)(cid:47)(cid:42)(cid:40)(cid:49)(cid:40)
`APOTEX v. CELGENE
`(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:21)(cid:22)(cid:16)(cid:19)(cid:19)(cid:24)(cid:20)(cid:21)
`IPR2023-00512
`
`

`

`IPR2023-00512
`Patent No. 8,846,628
`
`I, Amy K. Wigmore, declare as follows:
`
`li.
`
`I obtained a B.A.from the University of Massachusetts in 1992 and a
`
`J.D. from the Harvard Law Schoolin 1995.
`
`2.
`
`I am currently a partner in the law firm of Wilmer Cutler Pickering
`
`Hale and Dorr LLP.
`
`I was admitted to the Massachusetts Bar in January of 1996
`
`and the District of Columbia Bar in Decemberof 1996.
`
`I have been practicing
`
`law for over 20 years. For more than 15 years, my practice has focused primarily
`
`on patent litigation. Over the course of my career, I have been counsel in dozens
`
`of patentlitigations.
`
`3.
`
`I am a memberin goodstanding of the Bars of the Commonwealth of
`
`Massachusetts and District of Columbia.
`
`I am admitted to practice before the U.S.
`
`District Courts for the District of Columbia, District of Colorado, and District of
`
`Massachusetts.
`
`I am also admitted to practice before the U.S. Court of Appeals for
`
`the Federal Circuit, the D.C. Circuit, and the Sixth Circuit, as well as the Supreme
`
`Court of the United States.
`
`I am also admitted to practice before the District of
`
`Columbia Court of Appeal, the Supreme Judicial Court of Massachusetts, and the
`
`United States Court of Appeals for Veterans Claims.
`
`4.
`
`My Massachusetts Bar membership numberis 629275. MyDistrict
`
`of Columbia Bar membership numberis 453164.
`
`

`

`IPR2023-00512
`Patent No. 8,846,628
`
`5.
`
`[have appeared pro hacvice before the Office in the following
`
`proceedings: Apotex Inc. v. OSI Pharmaceuticals Inc., IPR2016-01284 (pro hae
`
`vice granted); OSI Pharmaceuticals, LLC v. Arch Development Corp., IPR2016-
`
`01034 (pro hac vice granted); Boehringer Ingelheim GmbH v. AbbVie
`
`Biotechnology Ltd., 1PR2016-00408 (pro hac vice granted); Boehringer Ingelheim
`
`GmbHv. AbbVie Biotechnology Ltd., IPR2016-00409 (pro hac vice granted);
`
`Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd., IPR2016-00188 (pro hac
`
`vice granted); Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd., 1PR2016-
`
`00189 (pro hac vice granted); Coherus BioSciences Inc. v. AbbVie Biotechnology
`
`Ltd., IPR2016-00172 (pro hac vice granted).
`
`6.
`
`] have an established familiarity with the subject matter of U.S. Patent
`
`No. 8,846,628 (the ’628 patent), the ’628 patent’s file history, and the priorart at
`
`issue in this proceeding.
`
`I am familiar with pharmaceutical technologiesas a
`
`result of participation as counselin related district court litigations on the ’628
`
`patent as well as many prior pharmaceutical-related intellectual property cases on
`
`behalf of Patent Owners and Bristol-Myers Squibb Co.
`
`I have also recently
`
`represented other pharmaceutical companies, including, amongothers, Exelixis,
`
`Inc., ModernaTX,Inc., and ModernaUS, Inc. in intellectual property matters
`
`before federal courts, including matters involving formulation technology.
`
`

`

`IPR2023-00512
`Patent No. 8,846,628
`
`4
`
`I have never been suspended ordisbarred from practice before any
`
`court or administrative body.
`
`8.|IThave never had a court or administrative body deny my application
`
`for admissionto practice.
`
`9.
`
`Ihave never had any sanctions or contemptcitations imposed on me
`
`by any court or administrative body.
`
`10.
`
` Lattest to each ofthe listed items required by the Order — Notice of
`
`Filing Date Accordedto Petition And Time ForFiling Patent Owner Preliminary
`
`Response in IPR2023-005 12.
`
`11.
`
`Ihave read and will comply with Office Patent Trial Practice Guide
`
`and the Board’s Rules of Practice for Trials, as set forth in 37 C.F.R. Part 42.
`
`12.
`
`Jlagree to be subject to the United States Patent and Trademark Office
`
`Rules of Professional Conductset forth in 37 C.F.R. §§ 11.101 et seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`I hereby declare that all statements made herein of my own knowledgeare
`
`true andthat all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledgethat willful false
`
`statements andthe like are punishable by fine, imprisonment, or both, under
`
`Section 1001 of Title 18 of the United States Code.
`
`

`

`Dated: October 31, 2023
`
`Respectfully submitted,
`:
`
`
`
`_dhreayKeliguanaAmy KVWigmore
`
`IPR2023-00512
`Patent No. 8,846,628
`
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`2100 Pennsylvania Ave NW
`Washington, DC, 20037
`Amy.Wigmore@wilmerhale.com
`Tel.: 202-663-6096
`Fax: 202-663-6363
`
`